Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

ClinicalTrials.gov ID: NCT03131453

Public ClinicalTrials.gov record NCT03131453. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

Study identification

NCT ID
NCT03131453
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,145 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
60 Years to 75 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 3, 2017 (Actual)
Primary completion
Mar 26, 2020 (Actual)
Completion
Mar 26, 2020 (Actual)
Last update posted
Aug 5, 2021

2017 – 2020

United States locations

U.S. sites
95
U.S. states
35
U.S. cities
86
Facility City State ZIP Site status
Banner Alzheimer's Institute, 901 East Willetta Street Phoenix Arizona 85006 —
Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B Sun City Arizona 85351 —
Novartis Investigative Site Tucson Arizona 85724 —
ATP Clinical Research Inc, 3151 Airway Avenue T 3 Costa Mesa California 92626 —
Irvine Center for Clinical Res, 2515 McCabe Way Irvine California 92618 —
Torrance Clinical Research Institute, 25043 Narbonne Avenue Lomita California 90717 —
Novartis Investigative Site Oxnard California 93030 —
Novartis Investigative Site Palo Alto California 94304 —
Novartis Investigative Site San Diego California 92103 —
Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130 Santa Ana California 92705 —
Novartis Investigative Site Sebastopol California 95472 —
Novartis Investigative Site Sherman Oaks California 91403 —
Mountain Neurological Research, 350 Market Street, Suite 316 Basalt Colorado 81621 —
Colorado Springs Neurological, 2312 North Nevada Avenue, Suite 100 Colorado Springs Colorado 80907 —
Denver Neurological Clinic, 950 E Harvard Ave Denver Colorado 80210 —
Yale University, One Church Street, Suite 600 New Haven Connecticut 06519 —
Novartis Investigative Site Stamford Connecticut 06905 —
Novartis Investigative Site Washington D.C. District of Columbia 20057 —
Novartis Investigative Site Atlantis Florida 33462-6608 —
Quantum Laboratories Deerfield Beach Florida 33064 —
Brain Matters Research, Inc., 800 NW 17th Avenue Delray Beach Florida 33445 —
Infinity Clinical Research LLC, 4925 Sheridan Street, Suite 200 Hollywood Florida 33021 —
Alzheimer's Research and Treatment Center, 5065 State Road 7, Suite 102 Lake Worth Florida 33449 —
Meridien Research, 2300 Maitland center, Pkwy Ste 230 Maitland Florida 32751 —
Novartis Investigative Site Melbourne Florida 32940 —
Novartis Investigative Site Merritt Island Florida 32952 —
Novartis Investigative Site Miami Florida 33032 —
Novartis Investigative Site Miami Florida 33136 —
New Horizon Research Center, 11880 SW 40 St., Suite 405 Miami Florida 33175 —
Miami-Dade Medical Research, 8955 SW 87 CT, Suite 112 Miami Florida 33176 —
Novartis Investigative Site Miami Beach Florida 33140 —
Compass Research, LLC,100 West Gore Street, Suite 202 Orlando Florida 32806 —
Novartis Investigative Site Orlando Florida 32806 —
Novartis Investigative Site Ormond Beach Florida 32174 —
Novartis Investigative Site Palm Beach Gardens Florida 33410 —
Novartis Investigative Site Port Orange Florida 32127 —
Roskamp Institute, Inc., 2040 Whitfield Avenue Sarasota Florida 34243 —
Novartis Investigative Site Tallahassee Florida 32308 —
Novartis Investigative Site Tampa Florida 33613 —
Novartis Investigative Site West Palm Beach Florida 33407 —
Novartis Investigative Site Atlanta Georgia 30322 —
Novartis Investigative Site Columbus Georgia 31909 —
Novartis Investigative Site Decatur Georgia 30033 —
Hawaii Pacific Neuroscience, 2230 Liliha st 104 Honolulu Hawaii 96817 —
Advanced Clinical Research, 2950 E Magic View Dr, Suite 182 Meridian Idaho 83642 —
Novartis Investigative Site Chicago Illinois 60612 —
Novartis Investigative Site Chicago Illinois 60640 —
Alexian Brothers Neuroscience, 800 Biesterfield Rd, Neuroscience Institute Brock Elk Grove Village Illinois 60007 —
Novartis Investigative Site Indianapolis Indiana 46202 —
Novartis Investigative Site Fairway Kansas 66205 —
Novartis Investigative Site Wichita Kansas 67206 —
Novartis Investigative Site Wichita Kansas 67214 —
Novartis Investigative Site Lexington Kentucky 40536-0284 —
Novartis Investigative Site Bangor Maine 04401 —
Novartis Investigative Site Boston Massachusetts 02118 —
Novartis Investigative Site Boston Massachusetts 02215 —
QUEST Research Institute, 28595 Orchard Lake Road, Suite 301 Farmington Hills Michigan 48334 —
Novartis Investigative Site Kalamazoo Michigan 49008 —
Novartis Investigative Site Rochester Minnesota 55905 —
Hattiesburg Clinic, 415 South 28th Avenue Hattiesburg Mississippi 39401 —
Novartis Investigative Site St Louis Missouri 63104 —
Novartis Investigative Site Omaha Nebraska 68198 7680 —
Novartis Investigative Site West Long Branch New Jersey 07764 —
Albuquerque Neuroscience, 101 Hospital Loop ne, 209 209 Albuquerque New Mexico 87109 —
Novartis Investigative Site Brooklyn New York 11235 —
Novartis Investigative Site East Syracuse New York 13057 —
Novartis Investigative Site Latham New York 12110 —
NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, Room 226 New York New York 10016 —
Novartis Investigative Site Orangeburg New York 10962 —
Novartis Investigative Site Rochester New York 14642 —
ANI Neurology, PLLC dba Alzhe, 7809 Sardis Road Charlotte North Carolina 28270 —
Novartis Investigative Site Durham North Carolina 27710 —
Novartis Investigative Site Greensboro North Carolina 27410 —
Novartis Investigative Site Cincinnati Ohio 45242 —
Novartis Investigative Site Oklahoma City Oklahoma 73112 —
Tulsa Clinical Research LLC, 1705 E 19th ST., STE 406/408 Tulsa Oklahoma 74104 —
Summit Research Network, 2701 NW Vaughn St, Suite 350 Portland Oregon 97210 —
Novartis Investigative Site Portland Oregon 97239 —
Novartis Investigative Site Jenkintown Pennsylvania 19046 —
Novartis Investigative Site Philadelphia Pennsylvania 19104 —
Abington Neurological Associate Ltd., 2325 Maryland Road, Suite 100 Willow Grove Pennsylvania 19090 —
Rhode Island Hospital and Memory Research Institute, 1018 Waterman Ave East Providence Rhode Island 02914 —
Butler Hospital, 345 Blackstone Blvd. Providence Rhode Island 02906 —
Roper Hospital, 316 Calhoun Street 5th Floor Charleston South Carolina 29401 —
Novartis Investigative Site Knoxville Tennessee 37920 —
Novartis Investigative Site Memphis Tennessee 38119 —
Novartis Investigative Site Nashville Tennessee 37212 —
Novartis Investigative Site Austin Texas 78757 —
Novartis Investigative Site Dallas Texas 75231 —
Novartis Investigative Site Houston Texas 77030 —
Novartis Investigative Site Houston Texas 77054 —
Novartis Investigative Site San Antonio Texas 78229 —
Novartis Investigative Site Bennington Vermont 05201 —
Novartis Investigative Site Tacoma Washington 98405 —
Novartis Investigative Site Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03131453, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 5, 2021 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03131453 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →